UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and APOTEX, INC., Petitioners,

v.

REGENERON PHARMACEUTICALS, INC., Patent Owner.

Inter Partes Review No.: IPR2021-008811

U.S. Patent No. 9,254,338 B2 Filed: July 12, 2013 Issued: February 9, 2016 Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS

Petitioner's Amended Mandatory Notices

¹ IPR2022-00258 and IPR2022-00298 have been joined with this proceeding.

DOCKE

Mylan Pharmaceuticals Inc. ("Petitioner") submits the following amended mandatory notices to identify additional related matters.

A. REAL PARTIES-IN-INTEREST (37 C.F.R. § 42.8(b)(1)).

Viatris Inc. and Mylan Inc. are parent companies of Petitioner Mylan Accordingly, Viatris Inc., Mylan Inc., and Mylan Pharmaceuticals Inc. Pharmaceuticals Inc. are identified as real parties-in-interest to the current Petition. Momenta Pharmaceuticals, Inc. and Janssen Research & Development LLC are Johnson wholly-owned subsidiaries of & Johnson, a publicly held company. Momenta Pharmaceuticals, Inc., Janssen Research & Development LLC, and Johnson & Johnson are also real parties-in-interest to the current Petition. No other parties exercised or could have exercised control over this Petition; no other parties funded, directed and controlled this Petition. See Trial Practice Guide, 77 Fed. Reg. 48759-60 (Aug. 14, 2021).

B. RELATED MATTERS (37 C.F.R. § 42.8(b)(2)) (AMENDED).

Petitioner identifies *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2021-00880 (P.T.A.B.), filed concurrently herewith. Petitioner also identifies *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2022-01225 (P.T.A.B.) and *Mylan Pharms. Inc. v. Regeneron Pharms., Inc.*, No. IPR2022-01226 (P.T.A.B.). To the best of Petitioner's knowledge, the following are judicial or administrative matters that would affect, or be affected by, a decision in this proceeding: *United*

States v. Regeneron Pharms., Inc., No. 1:20-cv-11217-FDS (D. Mass.) and Horizon
Healthcare Servs., Inc. v. Regeneron Pharms., Inc., No. 1:22-cv-10493-FDS (D. Mass.). Petitioner further identifies Chengdu Kanghong Biotechnology Co. v.
Regeneron Pharms., Inc., No. PGR2021-00035 (P.T.A.B.) out of an abundance of caution.

U.S. Patent Nos. 9,669,069 B2, 10,130,681 B2, 10,857,205 B2, 10,828,345 B2, and 10,888,601 B2; and U.S. Patent Application Nos. 17/072,417, 17/112,063, 17/112,404, 17/350,958, and 17/352,892 claim the benefit of the '338 patent filing date.

C. LEAD AND BACK-UP COUNSEL AND SERVICE INFORMATION (37 C.F.R. § 42.8(b)(3)-(4)).

Petitioner identifies its lead and backup counsel below.

Back-Up
William A. Rakoczy
(admitted pro hac vice)
wrakoczy@rmmslegal.com
Deanne M. Mazzochi (Reg. No. 50,158) dmazzochi@rmmslegal.com
Heinz J. Salmen
(admitted pro hac vice)
hsalmen@rmmslegal.com
Jeff A. Marx (Reg. No. 56,977) jmarx@rmmslegal.com
Eric R. Hunt
(admitted pro hac vice)
ehunt@rmmslegal.com
Neil B. McLaughlin (Reg. No. 70,810) nmclaughlin@rmmslegal.com
L. Scott Beall (Reg. No. 52,601) sbeall@rmmslegal.com
Thomas H. Ehrich (Reg. No. 67,122) tehrich@rmmslegal.com
Steven J. Birkos (Reg. No. 65,300) sbirkos@rmmslegal.com
Postal and Hand Delivery Address Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 222-5127

Please direct all correspondence to lead and back-up counsel at the contact information above. Petitioner also consents to service by email at: MYL REG IPR@rmmslegal.com.

Dated: July 18, 2022

DOCKE.

Δ

Respectfully Submitted,

RAKOCZY MOLINO MAZZOCHI SIWIK LLP

/Paul J. Molino/ Paul J. Molino Registration No. 45,350 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 222-6300 Facsimile: (312) 843-6260 paul@rmmslegal.com

Counsel for Petitioner

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.